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Background. Respiratory syncytial virus (RSV) is a leading cause of pediatric death, with >99% of mortality occurring in low- 
and lower middle-income countries. At least half of RSV-related deaths are estimated to occur in the community, but clinical char-
acteristics of this group of children remain poorly characterized. 
Methods. The RSV Global Online Mortality Database (RSV GOLD), a global registry of under-5 children who have died with 
RSV-related illness, describes clinical characteristics of children dying of RSV through global data sharing. RSV GOLD acts as a col-
laborative platform for global deaths, including community mortality studies described in this supplement. We aimed to compare 
the age distribution of infant deaths <6 months occurring in the community with in-hospital.
Results. We studied 829 RSV-related deaths <1 year of age from 38 developing countries, including 166 community deaths 
from 12 countries. There were 629 deaths that occurred <6 months, of which 156 (25%) occurred in the community. Among infants 
who died before 6 months of age, median age at death in the community (1.5 months; IQR: 0.8−3.3) was lower than in-hospital (2.4 
months; IQR: 1.5−4.0; P < .0001). The proportion of neonatal deaths was higher in the community (29%, 46/156) than in-hospital 
(12%, 57/473, P < 0.0001).
Conclusions. We observed that children in the community die at a younger age. We expect that maternal vaccination or 
immunoprophylaxis against RSV will have a larger impact on RSV-related mortality in the community than in-hospital. This case 
series of RSV-related community deaths, made possible through global data sharing, allowed us to assess the potential impact of 
future RSV vaccines.
Keywords:  community death; lower respiratory tract infection; respiratory syncytial virus.
As part of the global agenda for 2030 set by the United 
Nations, Sustainable Development Goal (SDG) 3 urgently 
calls for ending preventable deaths of children under 5 years 
of age. Globally, respiratory syncytial virus (RSV) is a leading 
cause of death after malaria for infants [1]. More than 99% of 
these RSV pediatric deaths occur in the developing world [2]. 
Current global mortality estimates are almost exclusively based 
on in-hospital RSV mortality. However, it is likely that a sig-
nificant proportion of these deaths occur outside the hospital, 
especially in low-income settings [3]. A recent meta-analysis 
estimated that out-of-hospital mortality was 2-fold higher 
than in-hospital mortality in 3 low-income and lower-middle-
income countries (L(M)ICs) [3]. Thus, the burden of out-of-
hospital RSV deaths appears to be at least as high as in-hospital 
deaths. Despite the magnitude of the problem, understanding 
aRSV GOLD collaborators are listed in the Notes section.
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the clinical characteristics of pediatric RSV-related mortality in 
the community remains a key knowledge gap.
Addressing the knowledge gap on community deaths can give 
key insights to inform policy for a future RSV vaccine. More 
than 50 vaccine candidates are in clinical development for RSV 
[4]. Different approaches to RSV prevention confer varying de-
grees and duration of protection. Currently, 2 major approaches 
are in development for infants: (1) maternal vaccination and (2) 
passive antibody prophylaxis. Recent late-phase trial data show 
the potential degree and duration of protection for these dif-
ferent approaches, with infant monoclonals giving a higher de-
gree and duration of protection than a maternal vaccine. The 
recently published phase III results of a post-fusion F protein 
maternal RSV vaccine show an antibody half-life of 49.1 days 
with 44.4% efficacy (95% confidence interval [CI]: 19.6-61.5%) 
against severe RSV lower respiratory tract infection (LRTI) 
through the first 3 months of life [5]. Prophylaxis with an ex-
tended half-life monoclonal antibody shows a longer duration 
of protection with 70.1% efficacy (95% CI: 52.3–81.2%) against 
RSV LRTI through the first 5 months of life [6]. To estimate the 
potential impact of RSV-preventive interventions against mor-
tality in the developing world, it is essential to characterize chil-
dren dying of RSV in the community.
Studying community deaths is difficult given the challenges as-
sociated with virological studies in deaths that occur in the com-
munity. To date, the largest case series of community RSV-related 
deaths includes 11 deaths at home in a single, urban setting in 
Argentina [7]. Although in-hospital deaths are challenging to cap-
ture in L(M)ICs given the lack of diagnostic capacity, capturing 
community deaths is even more challenging due to difficulty in 
ascertaining cause-of-death based on the low specificity of verbal 
autopsy data and difficulty obtaining postmortem patient samples. 
However, in the past years, several studies supported by the Bill & 
Melinda Gates Foundation (BMGF) aimed to measure RSV mor-
tality in the community: Z-PRIME (the Zambia Pertussis RSV 
Infant Mortality Estimation study); community-based studies in 
Argentina, India, and Pakistan; as well as the Child Health and 
Mortality Prevention Surveillance (CHAMPS) in South Africa, 
Bangladesh, Kenya, Mali, Mozambique, Ethiopia, and Sierra 
Leone [8]. The RSV Global Online Mortality Database (RSV 
GOLD) provides the unique opportunity to pool data from all of 
these studies and compare global individual-level patient data of 
children dying in the community to children dying in-hospital.
Respiratory syncytial virus–preventive interventions aim to 
prevent infant death in accordance with the SDGs. Estimated 
impact of a maternal vaccine or infant monoclonal on pediatric 
deaths will guide policy decisions and accelerate access to life-
saving interventions. The primary aim of this article is to de-
scribe global community pediatric deaths under 6 months and 
compare this group with in-hospital deaths in upper-middle-
income countries (UMICs) and L(M)ICs.
METHODS
Study Site, Design, and Population
RSV GOLD is a global online registry for children under the 
age of 5 years who died with laboratory-confirmed RSV infec-
tion after 1 January 1995 [9]. Individual patient-level data are 
collected using an online questionnaire. Variables collected in 
the RSV GOLD database have been published previously [9]. 
Data are collected through active outreach to researchers and 
physicians worldwide. Investigators of BMGF-funded com-
munity mortality studies were specifically asked to share data 
collected through 2 March 2021. The data from these com-
munity studies have been published in this supplement issue. 
Two community studies (Z-PRIME and Pakistan Community 
Mortality studies) included children younger than 6 months of 
age; other studies recruited children through at least 12 months 
of age (Supplementary Table 1). Data from studies submitted to 
the RSV GOLD registry were collected both prospectively and 
retrospectively.
In this analysis RSV-related deaths above 1 year of age, nos-
ocomial deaths, and deaths in high-income countries were ex-
cluded (Figure 1). Based on the expected duration of protection 
for infant RSV-preventive interventions, the primary aim of this 
study was to compare the age distribution of RSV-related infant 
deaths under 6 months occurring in the community with those 
in-hospital. The secondary aim was to describe age at death for 
children dying of RSV in the first year of life in the commu-
nity. In order to achieve our secondary aim, to describe the age 
distribution under 1 year, we analyze the population (“12m co-
hort”), in which we excluded 2 community studies that only en-
rolled children up to 6 months of age.
Data Collection and Case Definition
Case definitions of a community death varied between different 
BMGF-funded community mortality studies (Supplementary 
Table 1). For community deaths submitted to RSV GOLD that 
did not originate from these studies, a community death was 
defined as a child who did not die in the hospital or a child 
who was not hospitalized and location of death was unknown 
(n = 2). As in our previous publications, we included any death 
with laboratory-confirmed RSV infection and did not require 
RSV to be the primary cause of death (Supplementary Table 5) 
[9]. Neonates were defined as children through 1 month of age.
Upon submission to the database, data-quality checks were 
performed by the RSV GOLD team to ensure the completeness 
and accuracy of the data. To this end, case data were verified 
for missingness, plausibility, and accuracy through direct com-
munication with collaborators as soon as possible after case 
submission. Minimum essential data for inclusion were the key 
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Statistical Analyses
For continuous variables, the means or medians were re-
ported and differences between 2 groups were tested with 
a Mann-Whitney U test. Categorical variables were de-
scribed with frequencies and percentages and compared 
between groups using Fisher’s exact test. We did not per-
form imputation for missing data because data were not 
missing for essential variables and for other variables there 
was no clear correlation on which to build a multiple im-
putation model.
We considered P < .05 to be significant for all analyses. 
Despite multiple comparisons, we chose not to correct for 
an increased false-positive rate due to the exploratory na-
ture of the study and small sample size. The statistical anal-
ysis was performed using R version 4.0.2 (R Core Team 
2020, Vienna, Austria) with the following packages: ggplot2 
[10], ggpubr [11], rnaturalearthdata [12], dplyr [13], and 
qwraps2 [14].
We performed 2 sensitivity analyses: (1) without the 
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190 deaths excluded aged ≥6 months 10 deaths excluded aged ≥6 months
Figure 1. Flowchart  of children included in this study. Flowchart shows children excluded via both data quality and per definition of study population. For the primary anal-
ysis we analyzed 629 children dying under age 6 months (473 in-hospital deaths and 156 community deaths). For the secondary analysis we analyzed 661 children dying under 
age 12 months (611 in-hospital deaths and 50 community deaths). GOLD I: Pediatric deaths published as a retrospective case series from 1 November 2014 to 31 October 
2015 [9]. GOLD II includes pediatric deaths collected after this publication. Abbreviations: m, months; BMGF, Bill & Melinda Gates Foundation; GOLD, Global Online Mortality 
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mortality studies. As the majority of the data for community 
deaths originated from the Z-PRIME study in Zambia, we 
performed a sensitivity analysis that excluded the Z-PRIME 
cases to ensure that this overrepresentation of Zambia deaths 
did not lead to different results. Furthermore, we tested the 
assumption that community deaths from the Z-PRIME data 
are representative for community deaths from other L(M)
ICs by testing the observed characteristics for significant 
differences.
Ethical Considerations
The institutional research board of the University Medical 
Center Utrecht waived the requirement for parental in-
formed consent in 2014 since the study concerns only an-
onymized secondary data. Collaborators sharing data were 
encouraged to adhere to local standards for ethics approval 
in accordance with the RSV GOLD Ethics Guideline [15].
RESULTS
Study Population
The overall study population included 829 pediatric deaths under 
1 year of age from 38 countries classified as UMIC or L(M)IC 
according to the World Bank income group classification (Figure 
1, Supplementary Table 2). Of these, 166 deaths occurred in 
the community. The world maps in Figure 2A and 2B show the 
global distribution of community and in-hospital deaths, re-
spectively. The study population of infants under 6 months con-
sisted of 629 deaths, of which 156 (25%) deaths from 12 different 
countries occurred in the community (Supplementary Table 
4). Most community deaths were from Zambia (72%, 112/156). 
Community deaths were submitted from 2009 onwards, while 
data for in-hospital deaths were shared from 1995 onwards. The 
12m cohort comprises 661 children, of whom 8% (50/661) died 
in the community and 92% (611/661) died in-hospital.
Figure 2. A, World map showing L(M)ICs and UMICs that shared RSV-confirmed community deaths under 12 months of age and number of RSV-confirmed community 
deaths shared to the registry. The color gradient of purple indicates number of deaths shared, with darker purple representing increased number of deaths shared. Numbers 
of deaths are visible on the map. B, World map showing L(M)ICs and UMICs that shared RSV-confirmed in-hospital deaths under 12 months of age and number of deaths of 
RSV-confirmed in-hospital deaths shared to the registry. The color gradient of green indicates number of deaths shared, with darker green representing increased number 
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Age at Death of Community Versus In-Hospital Deaths
Median age at death was significantly lower for community 
deaths (1.5 months; IQR: 0.8−3.3) than in-hospital deaths 
(2.4 months; IQR: 1.5−4.0; P < .0001) (Table 1, Figure 3A). 
Deaths in the community included a higher proportion of 
neonates (29%, 46/156) than deaths occurring in-hospital 
(12%, 57/473; P < .0001). Similar results were found for the 
12m cohort (Table 2, Figure 3A). In the 12m cohort, me-
dian age at death was lower in the community (2.1 months; 
IQR: 1.3–5.0) compared with in-hospital (4.0 months; IQR: 
2.0–6.1; P = .02) (Table 2, Figure 3B). Similarly, for the 12m 
cohort, a higher proportion of deaths occurred in the neonatal 
period in the community (14%, 7/50) than in-hospital (7%, 
40/611), although this difference was not statistically signif-
icant (P = .08).
Clinical Characteristics of Community vs In-Hospital Deaths
For infants who died under 6 months, clinical characteristics of 
community and in-hospital deaths were largely comparable. For 
children under 6 months with comorbidity data, 31% (11/35) 
of infants dying in the community had a comorbidity com-
pared with 44% (162/368) who died in-hospital. However, data 
on comorbidities were missing for 78% of community deaths, 
limiting the power to analyze this characteristic (comorbidities 
are specified in Supplementary Table 8). The proportion of 
premature infants did not differ significantly between com-
munity (25%, 11/44) and in-hospital (32%, 81/253; not sig-
nificant) deaths. We note that prematurity data were missing 
for a substantial proportion of community (72% 112/156) and 
in-hospital (47%, 220/473) deaths for infants under 6 months. 
The reported mean gestational age was lower for deaths 
in-hospital compared with those occurring in the community 
(36.2 vs 38.5 weeks; P = .005).
The secondary analysis of the 12m cohort was remark-
ably similar to the primary analysis of children dying before 
age 6 months. Among infants dying in the community, 28% 
(10/36) had a comorbidity compared with 46% (240/525, 
P = .04) of infants dying in-hospital. In the 12m cohort, the 
proportion of premature infants did not differ significantly 
between community versus in-hospital deaths (Table 2), al-
though reported gestational age was significantly lower for 
infants dying in-hospital than in the community (36.3 vs 38.4 
weeks; P = .006).
Sensitivity Analyses
We performed a sensitivity analysis excluding the majority 
of the community deaths, which originated from a single 
Zambian study site (71%, 112/156). The age at death in the 
community did not differ significantly for children who died 
in Zambia (n = 112; data shown in Gill et al in this supplement 
issue) compared with children from other countries (n = 44; 
2.0 months; IQR: 1.3–3.3 months). The proportion of children 
with prematurity was similar for community deaths in Zambia 
and community deaths elsewhere (Forman et al, data pub-
lished elsewhere in this supplement issue). After excluding the 
Zambia data, we found that age at death remained lower for 
children who died in the community (2.0 months; IQR: 1.3–
3.3) compared with children who died in-hospital (2.5 months; 
IQR: 1.8–4.0), although this difference was not statistically sig-
nificant (P = .07) (Supplementary Table 6). The proportion of 
neonates was similar in the in-hospital and community deaths 
(Supplementary Table 6).
We performed a sensitivity analysis restricted to data 
obtained from the community mortality study sites (144 
community deaths and 68 in-hospital deaths) to rule out 
bias due to differences in methodology of data collection, 
because data in this subset were collected systematically in 
the community and in the hospital setting (Supplementary 
Table 7). In this analysis, we observed a lower median age 
at death in the community compared with in-hospital, al-
though differences were smaller than in the main analysis 
and not statistically significant (1.5 vs 2.0 months; P = .26). 
Table 1. Clinical Characteristics of Children Under 6 Months Who Died with Respiratory Syncytial Virus In-Hospital Versus in the Community in Lower-
income Middle-Income Countries and Upper-Middle-Income Countries
Clinical Characteristics All Deaths (n = 629) Community (n = 156) In-Hospital (n = 473) P
Sex, male, % (n/N) 54 (330/615) 55 (78/142) 53 (252/473) NS
Age at death, months, median (IQR) 2.0 (1.1-4.0) 1.5 (0.8-3.3) 2.4 (1.5-4.0) <.0001
Neonatal deaths, % (n/N) 16 (103/629) 29 (46/156) 12 (57/473) <.0001
Comorbidity, % (n/N) 43 (173/403) 31 (11/35) 44 (162/368) NS
Prematurity, % (n/N) 31 (92/297) 25 (11/44) 32 (81/253) NS
Gestational age, weeks, mean (SD, n) 36.6 (3.5, 145) 38.5 (2.4, 23) 36.2 (3.6, 122) .005
Birth weight, kg, median (IQR, n) 2.8 (2.2-3.2, 156) 3.0 (2.4-3.3, 30) 2.8 (2.2-3.2, 126) NS
Month and year of death, minimum–maximum July 1995–February 2021 February 2009–July 2020 July 1995–February 2021 …
Not immunized, % (n/N) 30 (71/235) 36 (15/42) 29 (56/193) NS
Other children in household, % (n/N) 75 (118/158) 82 (18/22) 74 (100/136) NS
Mother uneducated, % (n/N) 10 (23/231) 6 (6/103) 13 (17/128) NS
Father uneducated, % (n/N) 6 (9/161) 1 (1/86) 11 (8/75) .01
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Moreover, in this sensitivity analysis, the proportion of neo-
nates was similar in the in-hospital and community deaths 
(Supplementary Table 7).
DISCUSSION
As a result of global data sharing by collaborators, this study is 
the first global case series to compare RSV-related mortality in 
the community with in-hospital deaths in L(M)ICs and UMICs. 
The aim of this study was to understand differences between 
infants dying in the community and infants dying in-hospital in 
order to inform RSV vaccine–development strategies for low-
resource settings. We found that children dying in the commu-
nity were generally younger than children dying in-hospital. A 
larger proportion of deaths in the community involved neo-
nates in the primary analyses but not the sensitivity analyses, 
possibly due to a larger proportion of deaths originating from 
L(M)ICs in the community. The younger age at death in the 
community may be explained by difficulty of caregivers in rec-
ognizing respiratory danger signs at a younger age, resulting 
in delayed or no access to care for younger children with RSV 
LRTI. We conclude that RSV-prevention strategies targeting in-
fants in the first months of life will likely have a larger impact on 
mortality occurring in the community than in-hospital. Thus, 
we expect a high impact of infant RSV immunization strategies 
via maternal vaccination or infant immunoprophylaxis.
The RSV GOLD database serves as a platform that can bundle 
data from study sites around the world to allow for a high-level 
analysis of RSV-related mortality around the globe. Previous 
publications on community deaths did not describe age distri-
bution for RSV-related illness but instead described risk factors 
for community deaths in Argentina [7], leading causes of deaths 
determined by minimally invasive autopsies in the CHAMPS 
sites [8], and estimates of the proportion of out-of-hospital 
deaths in South Africa [16]. Previously we published a case se-
ries of in-hospital deaths in which we found the median age at 
death to be 5 months in L(M)ICs and 4 months in UMICs in 
children under 5 years of age. In this analysis, we found the me-
dian age at RSV-related death in infants from UMICs and  L(M)
ICs who died before 1 year of age to be similar (4.0 months; 
IQR: 2.0−6.1).
There were several limitations of this study. First, the commu-
nity mortality studies contributing to the RSV GOLD registry 
were not designed identically and used different definitions for 
community deaths (Supplementary Table 1). A second limita-
tion concerns the reporting of age at death by collaborators. 
There are 2 ways in which collaborators may have rounded age 
at death to age in months, which could introduce bias in our 
analysis. Due to general conceptualization of age, collaborators 
may have rounded age in months down. This rounding method 
may have introduced systematic bias for the group of children 
who died in-hospital because age at death was most frequently 
shared in months for in-hospital deaths and in days for com-
munity deaths. Second, collaborators may round age to the 
nearest integer, which would mean that the cutoffs applied for 
our analyses exclude children whose age was rounded to 1 (neo-
nates), 6 (primary analysis), or 12 (secondary analysis) months. 
Figure 3. A, Histogram and density plot of age at death for children under 6 months 
who died with RSV in the community compared with in-hospital in L(M)ICs and UMICs. 
The histogram shows number of deaths (count, left y-axis) shared to the registry by 
age at death in months (rounded to the nearest integer) from age 0 up to 6 months 
for all infants under 6 months of age. Lines show the kernel density estimate of age 
at death in months (density, right y-axis). Deaths that occurred in the community are 
shown in purple, while deaths that occurred in the hospital are shown in green. B, 
Histogram and density plot of age at RSV-related death for children under 12 months 
who died in the community compared with in-hospital in L(M)ICs and UMICs. The his-
togram shows number of deaths shared (count, left y-axis) to the registry by age at 
death from age 0 up to 12 months for the 12m cohort. Lines show the kernel density 
estimate of age at death in months (density, right y-axis). Deaths that occurred in the 
community are shown in purple, while deaths that occurred in the hospital are shown 
in green. Abbreviations: L(M)ICs, lower income and lower middle income country; RSV, 
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For example, the observed difference in proportion of neonatal 
deaths could be influenced by misclassification bias. To this end, 
age reported in months may have been rounded to age 1 month 
for deaths in the first month of life and subsequently these chil-
dren would not be classified as neonatal deaths more often for 
the in-hospital group. In summary, for both rounding methods, 
age at death may have been underestimated for children dying 
in the hospital, which would mean that the difference in age 
between community and in-hospital deaths may have been 
underestimated. A third limitation of the study is the quality 
and completeness of the data. An inherent weakness in global 
data sharing is that primary data cannot be verified and data-
collection systems differ in quality. With extensive data-quality 
checks and direct verification with collaborators, we attempted 
to limit the impact of this methodological weakness. For some 
variables (comorbidity, prematurity), a high proportion of data 
were missing.
More than 50% of community death data originate from a 
single study site (Zambia). Our conclusions regarding age at 
death did not change when excluding these deaths from the 
analysis. An important limitation is the difficulty of measuring 
mortality in the community, which may have resulted in missed 
deaths. Data from the community were from a small number 
of countries while hospital deaths were shared from a larger 
number of countries over a longer period of time, which may 
account for differences in the data. Data from most studies 
were obtained from systematic postmortem sampling, which 
may not be comparable to the way in which data were obtained 
for the in-hospital group and which could explain the different 
findings in the sensitivity analyses. For this reason, the age dif-
ference could also be explained by limitations in study meth-
odology as children with RSV may present with nonspecific 
symptoms to the hospital at a younger age and not be tested 
in L(M)ICs. However, in a sensitivity analyses limited to com-
parable groups in-hospital and in the community, we observed 
the same trend of lower age at death in the community. Despite 
data-quality verification processes, there are major limitations 
of the study methodology as published previously [9].
Future steps should consist of analysis of a larger case se-
ries including more community deaths and a larger global 
distribution, which will allow for more robust conclusions 
regarding vaccine impact on infant mortality. Prospective, 
real-time data sharing of RSV-related death in L(M)ICs will 
contribute to increased data quality and completeness of 
data, including more detailed information on age at death, 
allowing for a better comparison between community and 
in-hospital RSV-related deaths. A uniform definition of 
RSV-related deaths in the community will allow for better 
collection and understanding of global community mor-
tality. Future studies would be strengthened by enhanced 
systems for data collection of key clinical characteristics 
such as immunization status, prematurity, and comorbidity 
for community deaths, as this information was frequently 
missing for this population.
Conclusions
Community deaths are thought to represent more than half 
of all RSV-related deaths globally [17]. Characterizing these 
deaths is essential to estimate the impact of future preventive 
interventions. Due to global data sharing and efforts of BMGF-
funded community mortality studies and other collaborators, 
the RSV GOLD database has served as a platform to aggregate 
robust data for analysis of RSV-related pediatric mortality on 
a global level. We show that infants under 6 months of age die 
at a younger age in the community than in-hospital. Modeling 
studies will have to translate these findings into expected im-
pact of upcoming maternal vaccines and next-generation mon-
oclonal antibodies against RSV. For the first time, we show 
evidence that maternal vaccination or infant monoclonal pro-
phylaxis may have a greater impact on RSV-related community 
Table 2. Clinical Characteristics of Children Under 12 Months Who Died with Respiratory Syncytial Virus In-Hospital Versus in the Community in Lower-
Middle-Income Countries and Upper-Middle-Income Countries, Excluding Deaths From Studies Recruiting Only Those Under 6 Months
Clinical Characteristics All Deaths (n = 661) Community (n = 50) In-Hospital (n = 611) P
Sex, male, % (n/N) 56 (369/661) 56 (28/50) 56 (341/611) NS
Age at death, months, median (IQR) 4.0 (2.0-6.0) 2.1 (1.3-5.0) 4.0 (2.0-6.1) .02
 Neonatal deaths, % (n/N) 7 (47/661) 14 (7/50) 7 (40/611) NS
Deaths <6 months, % (n/N) 70 (461/661) 80 (40/50) 69 (421/611) NS
Comorbidity, % (n/N) 45 (250/561) 28 (10/36) 46 (240/525) .04
Prematurity, % (n/N) 28 (101/356) 24 (9/37) 29 (92/319) NS
Gestational age, weeks, mean (SD, n) 36.6 (3.5, 195) 38.4 (2.5, 27) 36.3 (3.5, 168) .01
Birth weight, kg, median (IQR, n) 2.8 (2.2-3.2, 208) 3.0 (2.5-3.3, 30) 2.8 (2.2-3.2, 178) NS
Month and year of death, minimum–maximum July 1995–February 2021 February 2009–February 2020 July 1995–February 2021 …
Not immunized, % (n/N) 13 (33/258) 19 (5/27) 12 (28/231) NS
Other children in household, % (n/N) 73 (160/220) 90 (19/21) 71 (141/199) NS
Mother uneducated, % (n/N) 12 (19/155) 8 (2/25) 13 (17/130) NS
Father uneducated, % (n/N) 7 (6/81) 5 (1/21) 8 (5/60) NS
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mortality than in-hospital mortality. Ultimately, clinical trials 
and postmarketing surveillance studies will provide further evi-
dence to evaluate the impact of these interventions on pediatric 
RSV mortality in the community versus in-hospital.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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